Does Ivabradine Benefit Diabetic Patients with Stable Angina?

The novel antianginal drug ivabradine, which was approved for use in Europe in 2005 but has not been FDA approved to date, lowers the heart rate through selective inhibition of the heart's If current. Previous studies demonstrated the drug's efficacy and safety in managing stable coronary artery disease (CAD) to be comparable to that of the beta-blocker atenolol and the calcium channel blocker amlodipine. But does this hold true specifically for patients with diabetes?